Tags : glycopyrronium/formoterol fumarate

Biotech Regulatory

AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) Receives NMPA’s Approval for Patients

Shots: The NMPA’s approval is based on P-III PINNACLE 4 study assessing Bevespi Aerosphere (bid via a pMDI) vs its monotherapy components (glycopyrronium and formoterol fumarate) and PBO in patients with moderate to very severe COPD The P-III PINNACLE 4 study demonstrated improvement in lung function as measured by trough forced expiratory volume in one […]Read More